Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Susumu Tazuma is active.

Publication


Featured researches published by Susumu Tazuma.


Journal of Hepato-biliary-pancreatic Sciences | 2012

Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012

Hirotaka Ohara; Kazuichi Okazaki; Hirohito Tsubouchi; Kazuo Inui; Shigeyuki Kawa; Terumi Kamisawa; Susumu Tazuma; Kazushige Uchida; Kenji Hirano; Hitoshi Yoshida; Takayoshi Nishino; Shigeru B. H. Ko; Nobumasa Mizuno; Hideaki Hamano; Atsushi Kanno; Kenji Notohara; Osamu Hasebe; Takahiro Nakazawa; Yasuni Nakanuma; Hajime Takikawa

BackgroundIgG4-sclerosing cholangitis (IgG4-SC) patients have an increased level of serum IgG4, dense infiltration of IgG4-positive plasma cells with extensive fibrosis in the bile duct wall, and a good response to steroid therapy. However, it is not easy to distinguish IgG4-SC from primary sclerosing cholangitis, pancreatic cancer, and cholangiocarcinoma on the basis of cholangiographic findings alone because various cholangiographic features of IgG4-SC are similar to those of the above progressive or malignant diseases.MethodsThe Research Committee of IgG4-related Diseases and the Research Committee of Intractable Diseases of Liver and Biliary Tract in association with the Ministry of Health, Labor and Welfare, Japan and the Japan Biliary Association have set up a working group consisting of researchers specializing in IgG4-SC, and established the new clinical diagnostic criteria of IgG4-SC 2012.ResultsThe diagnosis of IgG4-SC is based on the combination of the following 4 criteria: (1) characteristic biliary imaging findings, (2) elevation of serum IgG4 concentrations, (3) the coexistence of IgG4-related diseases except those of the biliary tract, and (4) characteristic histopathological features. Furthermore, the effectiveness of steroid therapy is an optional extra diagnostic criterion to confirm accurate diagnosis of IgG4-SC.ConclusionThese diagnostic criteria for IgG4-SC are useful in practice for general physicians and other nonspecialists.


Metabolism-clinical and Experimental | 2008

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

Hideyuki Hyogo; Susumu Tazuma; Koji Arihiro; Keiko Iwamoto; Yoshitaka Nabeshima; Motoki Inoue; Tomokazu Ishitobi; Michihiro Nonaka; Kazuaki Chayama

Nonalcoholic steatohepatitis (NASH) is the hepatic manifestation of the metabolic syndrome. Currently, there is no established therapy for NASH. The aim of the present study was to evaluate the efficacy of atorvastatin in the treatment of NASH associated with hyperlipidemia. This prospective study included 31 patients with biopsy-proven NASH with hyperlipidemia. Body mass index, serum lipids, liver function tests, fibrosis markers, and adipocytokines (adiponectin, leptin, tumor necrosis factor-alpha) were measured periodically during an open-label study of atorvastatin (10 mg daily) for 24 months. Standard weight-loss counseling was continued during the treatment period. Oral glucose tolerance test and liver density assessed by computerized tomography were performed before and after treatment. Follow-up liver biopsy was performed in 17 patients. All 31 patients had high cholesterol levels at baseline, and 20 also presented high triglyceride levels. The body mass index and serum glucose levels did not change during the treatment. After treatment, 23 patients (74.2%) presented normal transaminase levels. Adiponectin levels were significantly increased, and the levels of tumor necrosis factor-alpha were significantly decreased. However, leptin levels were not changed significantly. The concentration of long-chain fatty acids was decreased; and significant decreases were observed in C18:2,n-6 (linoleic acid, -21%) and C20:4,n-6 (arachidonic acid, -22%). Liver steatosis and nonalcoholic fatty liver disease activity score were significantly improved, whereas 4 patients had increased fibrosis stage. The NASH-related metabolic parameters improved with therapy, including fibrosis in some patients. However, 4 of 17 patients had progression of fibrosis over the 2-year period, with 3 of them progressing to stage 3. It is unclear whether this divergent response represents sampling error, heterogeneity in the population, or untreated postprandial hyperglyceridemia. Controlled trials are needed to further investigate and resolve this.


Journal of Gastroenterology and Hepatology | 2007

Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis

Hideyuki Hyogo; Sho-ichi Yamagishi; Keiko Iwamoto; Koji Arihiro; Masayoshi Takeuchi; Takashi Sato; Hidenori Ochi; Michihiro Nonaka; Yoshitaka Nabeshima; Motoki Inoue; Tomokazu Ishitobi; Kazuaki Chayama; Susumu Tazuma

Background and Aim:  Advanced glycation end products (AGE), senescent macroprotein derivatives formed at an accelerated rate in diabetes, play important roles in the pathogenesis of diabetic vascular complications. Recently, AGE have also been found to be involved in insulin resistance. Although non‐alcoholic steatohepatitis (NASH) is generally considered a hepatic manifestation of insulin resistance, there are no reports showing the link of AGE to NASH. The aim of this study was to evaluate the clinical significance of AGE in patients with NASH.


Digestive Diseases and Sciences | 2005

Hepatitis C Virus Core Protein Modulates Fatty Acid Metabolism and Thereby Causes Lipid Accumulation in the Liver

Atsushi Yamaguchi; Susumu Tazuma; Tomoji Nishioka; Waka Ohishi; Hideyuki Hyogo; Shuichi Nomura; Kazuaki Chayama

We studied the roles of hepatitis C virus (HCV) core protein in hepatic steatosis and changes in hepatic lipid metabolism. HCV core protein expression plasmid was transfected in HepG2 . Triacylglyceride (TG) and mRNA level associated with lipid metabolism were measured. Male C57BL/6 mice were infected with HCV core recombinant adenovirus and used for lipids and mRNA studies. In HCV core protein-expressing cells, peroxisome proliferator-activated receptor (PPAR)α, multidrug resistance protein (MDR) 3, and microsomal triglyceride transfer protein (MTP) were down-regulated 48 hr after transfection. In HCV core protein-expressing mice, hepatic TG content and hepatic thiobarbituric acid-reactive substances increased. PPARα, MDR2, acyl-CoA oxidase (AOX), and carnitine palmitoyl transferase-1 (CPT-1) were down-regulated. HCV core protein down-regulated lipid metabolism-associated gene expression, Mdr2, CPT, and AOX, accompanied by down-regulation of PPARα. There findings may contribute to the understanding of HCV-related steatosis, induction of reactive oxygen species, and carcinogenesis.


Inflammatory Bowel Diseases | 2005

Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of Vα14 natural killer T cells in mice

Yoshitaka Ueno; Shinji Tanaka; Masaharu Sumii; Sachiko Miyake; Susumu Tazuma; Masaru Taniguchi; Takashi Yamamura; Kazuaki Chayama

Background and Aims: V&agr;14 natural killer T (NKT) cells seem to play important roles in the development of various autoimmune diseases. However, the pathophysiologic role of NKT cells in inflammatory bowel disease remains unclear. To clarify the mechanism by which the activation of NKT cells mediates protection against intestinal inflammation, we investigated the antiinflammatory role of specifically activated V&agr;14 NKT cells by glycolipids in a mouse experimental model of colitis induced by dextran sulfate sodium (DSS). Methods: Colitis was induced in C57BL/6 mice by the oral administration of 1.5% DSS for 9 days. A single dose of OCH or &agr;‐galactosylceramide, a ligand for NKT cells, was administered on day 3 after the induction of colitis. Body weights and colonic mucosal injury were assessed in each glycolipid‐treated group. Interferon‐&ggr; and interleukin‐4 levels in the supernatants from colonic lamina propria lymphocytes (LPLs) were measured by enzyme‐linked immunosorbent assay. Results: The administration of a single dose of OCH attenuated colonic inflammation, as defined by body weights and histologic injury. The protective effects of OCH could not be observed in V&agr;14 NKT cell‐deficient mice. In vivo treatment with OCH had improved the interferon‐&ggr;/interleukin‐4 ratio from colonic LPLs on day 9 after DSS treatment. Conclusion: The present data indicated that the activation of V&agr;14 NKT cells by OCH plays a pivotal role in mediating intestinal inflammation via altered mucosal T‐helper type 1/type 2 responses. Therapeutic strategies that are designed to activate specifically V&agr;14 NKT cells may prove to be beneficial in treating intestinal inflammation.


Journal of Gastroenterology | 2008

Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.

Keiko Iwamoto; Keishi Kanno; Hideyuki Hyogo; Sho-ichi Yamagishi; Masayoshi Takeuchi; Susumu Tazuma; Kazuaki Chayama

BackgroundAdvanced glycation end products (AGEs), final reaction products of protein with sugars, are known to contribute to diabetes-related complications. We have recently demonstrated high levels of serum AGEs in patients with nonalcoholic steatohepatitis (NASH). However, direct evidence for the participation of AGEs in hepatic infl ammation and fibrosis has not been shown. To explore the pathogenesis of NASH, we examined the biological infl uence of AGEs on hepatic stellate cells (HSCs) in vitro.MethodsAn established human HSC line, LI90, was exposed to a glyceraldehyde-derived-AGE (glycer-AGE), and the phenotypical changes of the LI90 cells were investigated. Intracellular formation of reactive oxygen species (ROS) was measured using a fl uorescent probe. Cell proliferation was examined by MTS assay. Fibrogenic marker gene expression was analyzed by quantitative real-time polymerase chain reaction. The production of monocyte chemoattractant protein 1 (MCP-1) was assessed by enzyme-linked immunosorbent assay.ResultsThe expression of AGE receptor was confirmed in LI90 cells at the mRNA and protein levels. In addition to increasing intracellular ROS generation, glycer-AGE upregulated fibrogenic genes such as those encoding for α-smooth muscle actin, transforming growth factor-β1, and collagen type Iα2. The expression of MCP-1 mRNA in LI90 cells as well as its secretion into the culture medium was significantly increased in response to AGEs. These changes were attenuated by treatment with the antioxidant N-acetylcysteine.ConclusionsThese data indicate that AGEs induce ROS generation and intensify the proliferation and activation of HSCs, supporting the possibility that antioxidants may represent a promising treatment for prevention of the development of hepatic fibrosis in NASH.


Biochemical and Biophysical Research Communications | 2003

AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl4

Keishi Kanno; Susumu Tazuma; Kazuaki Chayama

The renin-angiotensin system has been shown to contribute to fibrogenesis in varieties of organs, including the liver. Here, we investigated whether the angiotensin II type 1A receptor (AT1A) is implicated in the development of liver fibrosis, using AT1A-deficient and wild-type (WT) mice. After single dose of carbon tetrachloride (CCl(4)), there were no significant differences between two groups with regard to hepatic inflammation and necrosis. After 4 weeks of treatment with CCl(4), histological examination revealed that AT1A-deficient mice showed less infiltration of inflammatory cells and less severe progression of liver fibrosis compared with WT mice. These findings were accompanied by the hepatic content of hydoxyproline and the expression of alpha-smooth muscle actin (alpha SMA). The level of transforming growth factor-beta 1 (TGF-beta 1) messenger RNA was markedly higher in WT mice when compared with AT1A-deficient mice. These results confirm that signaling via AT1A plays a pivotal role in hepatic fibrogenesis.


Journal of Hepato-biliary-pancreatic Sciences | 2014

Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan

Atsushi Tanaka; Susumu Tazuma; Kazuichi Okazaki; Hirohito Tsubouchi; Kazuo Inui; Hajime Takikawa

We previously conducted nationwide surveys for primary sclerosing cholangitis (PSC) in Japan, and demonstrated several characteristic features of Japanese PSC patients, yet patients with IgG4‐related sclerosing cholangitis (IgG4‐SC) might be misdiagnosed as PSC. Since the clinical diagnostic criteria of IgG4‐SC were established in 2012, we again conducted a nationwide survey to investigate the characteristics of PSC and IgG4‐SC lacking pancreatic involvement.


Hepatology Research | 2014

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.

Hideyuki Hyogo; Tadashi Ikegami; Katsutoshi Tokushige; Etsuko Hashimoto; Kazuo Inui; Yasushi Matsuzaki; Hironori Tokumo; Fumiaki Hino; Susumu Tazuma

Oxidative stress plays a pivotal role in the transition from simple steatosis to non‐alcoholic steatohepatitis (NASH). Probucol is a lipid‐lowering agent with strong antioxidant properties, and is reported to be effective for the treatment of NASH in several studies. The aim of the present study was to evaluate the efficacy of probucol for the treatment of NASH with dyslipidemia.


Digestive Diseases and Sciences | 2005

Angiotensin II Participates in Hepatic Inflammation and Fibrosis through MCP-1 Expression

Keishi Kanno; Susumu Tazuma; Tomoji Nishioka; Hideyuki Hyogo; Kazuaki Chayama

In this study, we assessed the hypothesis that angiotensin (Ang) II could modulate inflammatory cell recruitment into the liver through hepatic expression of monocyte chemoattractant protein (MCP)-1 during liver injury. For in vivo study, Ang II type 1a knockout (AT1a KO) mice and wild-type (WT) mice were treated with CCl4 for 4 weeks. After CCl4 treatment, AT1a KO mice showed lower expression of MCP-1 and fewer CD68-positive cells in the liver compared with WT mice. For in vitro study, Ang II was added to LI90 cells. Ang II enhanced MCP-1 mRNA together with RhoA mRNA and also induced secretion of MCP-1 into the culture medium. This change was strongly blocked by Y-27632, a specific Rho-kinase inhibitor. These results suggest that Ang II modulates hepatic inflammation via production of MCP-1 by hepatic stellate cells, and the effect of Ang II on MCP-1 production is, at least partly, mediated by the Rho/Rho-kinase pathway.

Collaboration


Dive into the Susumu Tazuma's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kazuo Inui

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge